Disease Info Card

Long Qt Syndrome Congenital

Information about Long Qt Syndrome Congenital: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Long Qt Syndrome Congenital

Most recent studies have shown that Long Qt Syndrome Congenital shares some biological mechanisms with atrioventricular-block, bradycardia, brugada-syndrome-(disorder), cardiac-arrest, cardiac-arrhythmia, cardiac-death, cardiac-fibrillation, cardiomyopathies, channelopathies, heart-diseases, long-qt-syndrome, malignant-paraganglionic-neoplasm, polymorphic-ventricular-tachycardia, sudden-cardiac-death, sudden-death, syncope, tachycardia-ventricular, torsades-de-pointes, ventricular-arrhythmia, ventricular-fibrillation.

Among the many pathways, these few ones have gauged particular interests from scientists studying Long Qt Syndrome Congenital, and have been seen in publications frequently: Aldosterone Secretion, Cardiac Conduction, Cellular Localization, Circadian Rhythm, Glycosylation, Innervation, Insulin Secretion, Localization, Pathogenesis, Protein Folding, Protein Phosphorylation, Proteolysis, Rna Interference, Secretion, Swimming, Transport

Quite a number of genes have been found to play important roles in Long Qt Syndrome Congenital, such as CAV3, COL18A1, ERG, GNL3, KCNA4, KCNA5, KCNE1, KCNE2, KCNH1, KCNH2, KCNH6, KCNK3, KCNQ1, MINK1, OXSM, SCD, SCN5A. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.